These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 21794790

  • 1. [Descriptive study of the use of DMARD in patients with rheumatoid arthritis or persistent arthritis who start drug treatment in Spain (FIRST)].
    Blanco FJ, Ballina J, Carbonell J, Martín-Mola E, Tornero J, Ramírez E, Galván J.
    Reumatol Clin; 2011; 7(2):88-93. PubMed ID: 21794790
    [Abstract] [Full Text] [Related]

  • 2. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T, Pincus T.
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [Abstract] [Full Text] [Related]

  • 3. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA, RADIUS Investigators.
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [Abstract] [Full Text] [Related]

  • 4. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
    Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, Levin R, Solomon DH.
    Arthritis Rheum; 2007 Aug 15; 57(6):928-34. PubMed ID: 17665462
    [Abstract] [Full Text] [Related]

  • 5. Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience.
    Cardiel MH, Pons-Estel BA, Sacnun MP, Wojdyla D, Saurit V, Marcos JC, Pinto MR, Cordeiro de Azevedo AB, da Silveira IG, Radominski SC, Ximenes AC, Massardo L, Ballesteros F, Rojas-Villarraga A, Oñate RV, Hernandez MP, Esquivel-Valerio JA, García-De La Torre I, Khoury VJ, Millán A, Soriano ER, GLADAR.
    J Clin Rheumatol; 2012 Oct 15; 18(7):327-35. PubMed ID: 23047532
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, Klassen LW, Wees S, Moore GF.
    J Rheumatol Suppl; 1996 Mar 15; 44():72-4. PubMed ID: 8833058
    [Abstract] [Full Text] [Related]

  • 7. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M, Akkasilpa S, Deesomchok U.
    J Med Assoc Thai; 2000 Mar 15; 83(3):217-24. PubMed ID: 10808674
    [Abstract] [Full Text] [Related]

  • 8. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X, EMECAR Study Group.
    J Rheumatol; 2003 Apr 15; 30(4):697-704. PubMed ID: 12672186
    [Abstract] [Full Text] [Related]

  • 9. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA.
    Curr Med Res Opin; 2006 Jan 15; 22(1):169-83. PubMed ID: 16393443
    [Abstract] [Full Text] [Related]

  • 10. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T, FIN-RACo Trial Group.
    Arthritis Rheum; 2009 May 15; 60(5):1222-31. PubMed ID: 19404945
    [Abstract] [Full Text] [Related]

  • 11. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA, Bingham CO.
    Semin Arthritis Rheum; 2005 Dec 15; 35(3):185-96. PubMed ID: 16325659
    [Abstract] [Full Text] [Related]

  • 12. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC.
    Scand J Rheumatol; 2009 Dec 15; 38(4):240-5. PubMed ID: 19229766
    [Abstract] [Full Text] [Related]

  • 13. Prescription rheumatology practices among Mexican specialists.
    Goycochea-Robles MV, Arce-Salinas CA, Guzmán-Vázquez S, Cardiel-Ríos MH.
    Arch Med Res; 2007 Apr 15; 38(3):354-9. PubMed ID: 17350489
    [Abstract] [Full Text] [Related]

  • 14. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE.
    Arthritis Res Ther; 2006 Apr 15; 8(5):R151. PubMed ID: 16984661
    [Abstract] [Full Text] [Related]

  • 15. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists.
    Zink A, Listing J, Ziemer S, Zeidler H, German Collaborative Arthritis Centres.
    J Rheumatol; 2001 Oct 15; 28(10):2201-8. PubMed ID: 11669156
    [Abstract] [Full Text] [Related]

  • 16. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.
    Clin Ther; 2009 Aug 15; 31(8):1737-46. PubMed ID: 19808132
    [Abstract] [Full Text] [Related]

  • 17. Advance and unmet need of health care for patients with rheumatoid arthritis in the German population--results from the German Rheumatoid Arthritis Population Survey (GRAPS).
    Westhoff G, Schneider M, Raspe H, Zeidler H, Runge C, Volmer T, Zink A.
    Rheumatology (Oxford); 2009 Jun 15; 48(6):650-7. PubMed ID: 19321515
    [Abstract] [Full Text] [Related]

  • 18. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
    Yazici Y, Shi N, John A.
    Bull NYU Hosp Jt Dis; 2008 Jun 15; 66(2):77-85. PubMed ID: 18537774
    [Abstract] [Full Text] [Related]

  • 19. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Agarwal S, Zaman T, Handa R.
    Singapore Med J; 2009 Jul 15; 50(7):686-92. PubMed ID: 19644623
    [Abstract] [Full Text] [Related]

  • 20. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE.
    J Rheumatol; 2006 Feb 15; 33(2):248-55. PubMed ID: 16358365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.